September 2010

The Obesity Society Newsletter
September 2010
Register Now for Obesity 2010!
Advocacy Forum at Obesity 2010
TOS 2010 Election Results
CORE Pre-Conference Seminar
2010 Grant Recipients
TOS Members and Obesity in the News
This Month in OBESITY
Article Headline


Obesity 2010


August 31-September 10, 2010:
International Course in Nutritional Epidemiology (2nd ed.)
Imperial College, London
Full Details 

September 16-19, 2010:: IASO Scope Summer School
Cambridge, UK
Full Details
September 21, 2010:: Institute of Medicine: Chicago Regional Membership Meeting: Diabetes and Obesity
Chicago, IL
Full Details 
September 28-30, 2010:: American Association of Diabetes Educators: Core Concepts - Seminar on Diabetes and Diabetes Self-Management
Orlando, FL
Full Details
September 28-30, 2010:: *The World Congress - 5th Annual Obesity Congress
Washington, DC
Full Details
(*Discount offered to TOS members)

September 29- October 1, 2010::
National Association of Bariatric Nurses: 7th Annual Meeting & Conference
Norfolk, VA
Full Details 
facebook image


GoodSearch: You Search...We Give!

Donna Ryan, MDDear TOS Members and Supporters,

 When the Going Gets Tough...
For this newsletter, I decided to write about something that has been at the top of my thoughts recently - the tough going many obesity agents are having before the FDA.  I realize that our membership is a broad constituency, but this topic is something that can affect all of us.  
The combination of two approved drugs, topiramate/phentermine, was given a mixed vote for approval at the FDA Panel assembled to hear evidence of its efficacy and safety, with the majority voting not to approve.  This action is puzzling, since both medications have been used widely - one for migraine prevention and the other for short-term treatment of obesity - and, since there was impressive evidence for efficacy. The company, Vivus, presented data on three doses. The highest dose (still only half of the recommended dose for each drug individually) did have low rates (1 percent) of nephrolithiasis and mild metabolic acidosis (due to the carbonic anhydrate inhibition function of topiramate).  The low and middle dose had less weight loss, but a much-better profile for tolerability and safety. The ultimate fate of the drug is unknown, as the FDA continues its review.
The long-awaited results of the SCOUT trial were published in the New England Journal of Medicine (September 2, 2010) with an accompanying editorial.  The large (n>9000) study in patients with diabetes and/or pre-existing cardiovascular disease (CVD) was designed to assess, following a 6-week run-in with drug, the effect of randomization to sibutramine or placebo on cardiovascular events. Several remarkable findings of SCOUT include the low event rate over an average of 3.4 years for the placebo group (only 10 percent) compared with sibutramine (11.4 percent); the lack of increased risk in the diabetic patients without CVD; the maintenance of weight loss after randomization to placebo; and, the continuation of the drug whether patients lost weight or not. One thing is clear; as indicated on the label, sibutramine should not be used in patients with cardiovascular disease.  But should the results of the SCOUT trial be generalized to patients with cardiovascular disease?  Patients at risk for diabetes, with sleep apnea, or with arthritis can all benefit from weight loss.  The FDA will hear the SCOUT data and determine the fate of sibutramine for those patients.
Two other medications will also be reviewed at FDA panels - lorcaserin on July 16 and, later in the year, the combination bupropion/naltrexone. It is clear from the first panel held this year that these medications face an uphill fight.  
If you listen to the FDA Panel proceedings when obesity drugs are reviewed, you will notice that the fundamental legitimacy of these drugs is questioned.  Panelists do not uniformly appreciate the risks of obesity, the benefits of weight loss, especially modest weight loss, and question the need for medications to help more patients achieve meaningful weight loss. That is an important observation for all of us to notice. The members of The Obesity Society have made progress over the last decade in demonstrating the multiple risks of overweight and obesity, the mechanisms of how obesity mediates risk, the benefits of modest weight loss in all levels of overweight and obesity, and the role that obesity surgery can play in managing obesity. Clearly, we have a way to go in disseminating that knowledge.
While the going is tough right now for obesity drugs, I believe that the tough will get going, and we will find safe and effective medications to help our patients who need it the most - obese patients with comorbidities.  
It takes a team - basic, clinical and population scientists - to address the challenges of understanding obesity and its comorbidities.  The greatest strength of our Society is the multidisciplinary assemblage we encompass and each discipline is an essential part. 

Donna Ryan Signature
Donna H. Ryan, MD
President, The Obesity Society
Register Now to Save With the Pre-Show Rate! 
Click here to register for Obesity 2010, the largest and most-comprehensive program in the field of obesity. Plan your time in San Diego at this year's annual meeting with the Advance Program.


Advocacy Forum at Obesity 2010 Will Discuss Role TOS Can Play
Health reform's passage means obesity is getting more attention than ever. Learn from policy experts what's coming, what's needed, and how The Obesity Society can make an impact.
Health Reform:
Getting Serious About Obesity
2:00 PM - 5:30 PM
San Diego Convention Center
Chair, Ted Kyle brings a panel of distinguished speakers to the table in this session that outlines the implications of reform for obesity research and treatment and will help define TOS' role in obesity policy development. Speakers include Dr. Amanda Cash from the Department of Health and Human Services; Christine Ferguson from The George Washington University School of Public Health and STOP Obesity Alliance; Dr. Kelly Brownell from the Yale University-Rudd Center for Food Policy and Obesity; Joseph Nadglowski, Jr from the Obesity Action Coalition; Geraldine Henchy from the
Food Research Action Center and Dr. George Bray from Pennington Biomedical Research Center
Co-Sponsors of the event:
»» Obesity Action Coalition
»» STOP Obesity Alliance
The Results Are Now In for 2010 Council and Nominating Committee

In a closely fought election this year, the following were elected by the members of The Obesity Society for Council and the Nominating Committee. Congratulations to all!
Vice President
Harvey Grill, PhD
Population/Epidemiology Councilor
Nancy Butte, PhD

Clinical/Translational Councilor
David Heber, MD, PhD
Basic/Experimental Councilor
Naima Moustaid-Moussa, PhD
Nominating Committee
Shiriki Kumanyika, PhD
June Stevens, PhD, RD
Nikhil Dhurandhar, PhD
Thanks to all the candidates who participated in the election, your willingness to serve is greatly appreciated.  
 Childhood Obesity Banner
Improve Your Practice: Learn the Latest About Clinical Obesity Management at CORE
CORE Pre-Conference Session 2010: Registration Deadline Approaching

The Centers for Obesity Research and Education (CORE), an educational arm
of The Obesity Society, will host a one day pre-conference CME course on Friday, October 8, 2010, to educate clinicians in weight management so you can provide better care to your patients.
The seminar includes didactic sessions from national leaders in obesity treatment, covering practical topics in clinical obesity management.  Attendees will discover the latest treatment options, including behavioral management, diet and physical activity, pharmacotherapy, and surgical treatment, then take a look into the future of obesity treatment. The Obesity Society designates this educational activity for a maximum of 7.0 AMA PRA Category 1 Credits TM. 

Pre-show registration for CORE ends September 16th, 2010 at midnight PST, so sign up now! And if you register for the CORE one-day, pre-conference Session you will receive a discount on registration for The Obesity Society's Annual Scientific Meeting. To register, please see the registration information on the Obesity 2010 site at: 
We hope you will join us for this exceptional meeting,
Ken Fujioka
Chair, Clinical Management Section
The Obesity Society

For complete program information, please visit
  Recipients Will Be Honored at Annual Meeting in October
 Nutrisystem, Inc., a leading provider of structured meal programs for weight loss and weight maintenance.  Randomized, controlled clinical studies using the complete Nutrisystem® program(s) to explore the following possibilities: (1) Effects of weight loss using a Nutrisystem program on disease risk or management; (2) Effects of weight loss using the Nutrisystem-D plan on Diabetes or Pre-Diabetes; and (3) Role of Nutrisystem® meal replacements as a weight maintenance aid. An award of $25,000 is given to the recipient for a one-year pilot study. Selected by the Obesity Society as the recipient of the inaugural award is:
Alison_GSK Recipient
Kelly H. Webber, PhD
University of Kentucky
Lexington, KY
The Effect of a Behavioral Weight-Loss Program With Nutrisystem Meal Provision on Change in Weight, Fasting Blood Glucose, Cholesterol, and Blood Pressure Over 12 Weeks
Co-Investigator: Stephanie Rose, MD 
A request for proposal for up to two such awards from Nutrisystem will appear in this newsletter in 2011.
 This grant mechanism is for both clinical and in vitro research:
Visceral Obesity - The relationship of central obesity to metabolic health continues to be an area of active research.  Focus on advancing the knowledge about this link and implications for therapy.
Behavioral Science Research - Successful intervention for weight loss and maintenance require a strong behavioral component.  Focus on the development and/or validation of novel and innovative tools for weight loss and/or maintenance.  Exploring how technology drives health behavior change.
Awards of $25,000 each are given to recipients for a one-year pilot study.
 Visceral Obesity
Alison_GSK Recipient
Anjel Vahratian, PhD, MPH
University of Michigan
Ann Arbor, MI
Maternal Visceral Fat and Metabolic Dysregulation During Pregnancy
Co-Investigator: Marjorie C. Treadwell, MD

 Behavioral Science Research

Alison_GSK RecipientKelly C. Allison, PhD
University of Pennsylvania School of Medicine
Philadelphia, PA
Preventing Excess Weight Gain During Pregnancy Using Integrated Technologies
Co-Investigators: Sindhu K. Srinivas, MD, MSCE and David B. Sarwer, PhD

 This program (formerly, New Investigator Research Grants) funds studies proposed by new investigators who have completed their doctorates (or residency training) within the past five years.  Awards of $25,000 each are given to the recipients for a one-year pilot study.

Alison_GSK RecipientKent C. Hansen, PhD
University of Colorado Denver
Aurora, CO
The Effects of Estrogen on Adipogenesis
Mentors: Wendy Kohrt, PhD and Dwight Klemm, PhD 
Co-Investigators: Wendee Gozansky, MD

Alison_GSK RecipientScott E. Kanoski, PhD
University of Pennsylvania
Philadelphia, PA
Ventral Hippocampal Leptin Signaling: The Higher-Order Controls of Food Intake Suppression
Mentor: Harvey J. Grill, PhD


Alison_GSK RecipientJennifer J. Otten, PhD, RD


Stanford School of Medicine
Santa Cruz, CA
Assessing the Impacts of the 2010 Santa Clara County, CA Ordinance Banning Toys and Other Incentives That Accompany Less Healthful Children's Menu Items
Co-Investigators:  Christopher Gardner, PhD, Matt Buman, PhD
  Here is a round-up of press articles that refer to The Obesity Society and its members or to topics relating to obesity in general. Please note that all external links are provided as a courtesy and do not constitute an endorsement by The Obesity Society.
 TOS and TOS Members in the News 
Dr. Steven Mittelman
Drs. Barry Popkin and Carla Wolper

Obesity September 2010THIS MONTH IN OBESITY

 September 2010
Featured Articles in Obesity This Month Include:
About Us
The Obesity Society extends special thanks and appreciation to all our sponsors who continue to support us in our mission.

The Obesity Society                                       
8630 Fenton Street
Suite 814
Silver Spring, Maryland 20910
301-563-6526 phone
301-563-6595 fax
If you have questions or information for potential inclusion in the newsletter, please let us know:
Jane Pratt, Director of Communications
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Lauren Davis, Communications Assistant
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
The Obesity Society
(Please note: External Links are provided as a courtesy. The Obesity Society is not responsible for the content on sites accessed through external links.)

clinician directory


obesity links


300x250 websitebanner